Foscarnet Sodium Market

The Foscarnet Sodium market is projected to grow at a CAGR of 4.7% from 2025 to 2035, driven by the increasing incidence of cytomegalovirus (CMV) infections in immunocompromised patients, particularly those undergoing organ transplants, bone marrow transplants, or living with HIV/AIDS.

Foscarnet Sodium, a pyrophosphate analog, acts as a broad-spectrum antiviral by directly inhibiting viral DNA polymerase, making it especially valuable in cases resistant to nucleoside analogues like ganciclovir. It is a crucial second-line therapy for acyclovir-resistant herpes simplex virus (HSV) and ganciclovir-resistant CMV, often administered intravenously in hospital settings due to its potent antiviral activity and specific toxicity profile requiring renal monitoring.

Regionally, North America leads the market, particularly the United States, due to high rates of transplant procedures and comprehensive infectious disease management infrastructure. The presence of leading academic centers and pharmaceutical companies also drives innovation and clinical adoption.

Europe holds a significant share, with countries like Germany, France, and the UK routinely incorporating Foscarnet into transplant infection protocols and HIV/AIDS care regimens. Asia-Pacific is an emerging market, with increasing transplant rates in Japan, China, and South Korea, and growing awareness of antiviral resistance.

These countries are also investing in better hospital-based infectious disease management, which supports Foscarnet uptake. In Latin America, especially Brazil and Argentina, Foscarnet is being gradually introduced into tertiary care centers. The Middle East & Africa present nascent markets, where awareness and diagnosis of CMV and HSV complications in immunocompromised populations are improving, especially in urban hospitals.